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عوامل و نسبة حدوث  اإلصابة بالركود الصفراوي املرتبط بالتغذية الوريدية يف 
األطفال العمانيني حديثي الوالدة
خربة مركز
�رشيف �رشيف، �سهام ال�سنانية، خالد النعماين، اإبراهيم الزكواين، زنيدة �ض. ري�ض، هالل الريامي، اأ�سفق اأ. خان، وطفة املعمرية
abstract: Objectives: Parenteral nutrition-associated cholestasis (PNAC) is one of the most challenging 
complications of prolonged parenteral nutrition (PN) in neonates. There is a lack of research investigating its 
incidence in newborn infants in Oman and the Arab region. Therefore, this study aimed to assess the incidence 
of PNAC and its risk factors in Omani neonates. Methods: This retrospective study took place between January 
and April 2014. All neonates who received PN for ≥14 days during a four-year period (June 2009 to May 2013) 
at the neonatal intensive care unit (NICU) in Sultan Qaboos University Hospital, Muscat, Oman, were enrolled. 
Results: A total of 1,857 neonates were admitted to the NICU over the study period and 135 neonates (7.3%) 
received PN for ≥14 days. Determining the incidence of PNAC was only possible in 97 neonates; of these, 38 (39%) 
had PNAC. The main risk factors associated with PNAC were duration of PN, duration of enteral starvation, 
gastrointestinal surgeries, blood transfusions and sepsis. Neonates with PNAC had a slightly higher incidence of 
necrotising enterocolitis in comparison to those without PNAC. Conclusion: This study found a PNAC incidence 
of 39% in Omani neonates. There were several significant risk factors for PNAC in Omani neonates; however, after 
logistic regression analysis, only total PN duration remained statistically significant. Preventive strategies should be 
implemented in NICUs so as to avoid future chronic liver disease in this population.
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امللخ�ص: الهدف: يعترب الركود ال�سفراوي من اأكرث م�ساعفات ا�ستخدام التغذية الوريدية لفرتات طويلة يف االأطفال حديثي الوالدة  حتديا. 
ال توجد درا�سات تبحث ن�سبة ومعدالت حدوثه يف الدول العربية و�سلطنة عمان. هدفت هذة الدرا�سة اىل حتديد معدالت االإ�سابة بالركود 
ال�سفراوي املرتبط باالإ�ستخدام املطول للتغذية الوريدية وم�سبباته يف االأطفال العمانيني حديثي الوالدة.  الطريقة: اأجريت هذه الدرا�سة 
االإ�سرتجاعية خالل الفرتة من �سهر يناير اىل اأبريل 2014. ومت ح�رش كل االأطفال العمانيني حديثي الوالدة والذين تلقوا التغذية الوريدية 
لفرتة اأطول من اأو ت�ساوي 14 يوم خالل فرتة 4 �سنوات بني يونيو 2009 وحتى مايو 2013 يف وحدة العناية املركزة  لالأطفال حديثي 
الوالدة مب�ست�سفى جامعة ال�سلطان قابو�ض مب�سقط، �سلطنة عمان. النتائج: مت ح�رش عدد 1,857 طفال حديث الوالدة اأدخلوا الوحدة لتلقي 
العناية خالل فرتة احل�رش. تلقى135 منهم التغذية الوريدية لفرتة اأطول من اأو ت�ساوي 14 يوم بن�سبة مئوية تعادل %7.3. حتديد معدل 
اأكرث عوامل االإ�سابة بالركود  ) %39(. كانت  38 طفل  ال�سفراوي يف  الركود  97 طفال فقط حيث حدث  ال�سفراوي كان ممكنا يف  الركود 
ال�سفراوي �سيوعا هي مدة تلقي التغذية الوريدية، مدة املجاعة املعوية، تعر�ض اجلهاز اله�سمي للعمليات اجلراحية ،  نقل الدم وحدوث 
باإلتهاب االمعاء  الوالدة امل�سابني  ال�سفراوي، حديثي  الوالدة والذين مل ي�سابوا بالركود  الدم. وباملقارنة لالأطفال حديثي  اإلتهاب يف 
والقولون الناخر  كانوا اأكرث عر�سه حلدوث الركود ال�سفراوي املرتبط بالتغذية  الوريدية.  اخلال�صة: حددت هذة الدرا�سة حدوث الركود 
ال�سفراوي املرتبط بالتغذية  الوريدية بن�سبة %39 يف االأطفال العمانيني حديثي الوالدة املتلقني للتغذية الوريدية وقد مت ح�رش العديد من 
عوامل االإ�سابة ولكن بعد اإ�ستخدام حتليل االإنحدار اللوج�ستي وجد اأن مدة التغذية الوريدية هو العامل الذي ظل له داللة اإح�سائية هامة. 
من املهم تنفيذ اإ�سرتاتيجيات وقائية يف وحدات العناية املركزة لالأطفال حديثي الوالدة لتجنب حدوث اأمرا�ض الكبد املزمنة م�ستقبال يف 
هذة الفئة. 
مفتاح الكلمات: الركود ال�سفراوي؛ التغذية الوريدية؛ حديثي الوالدة؛ معدل حدوث؛ عوامل االإ�سابة؛ عمان.
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In Oman, the use of parenteral nutrition (PN) in neonatal intensive care units (NICUs) is increasingly practiced as preterm infants as 
young as 24 gestational weeks are resuscitated. PN 
has fundamentally changed the care of neonates who 
cannot achieve adequate growth through enteral 
feeding.1 Today, many patients in different age groups 
depend on PN for their survival.
Parenteral nutrition-associated cholestasis (PNAC) 
is one of the most challenging complications arising 
from the prolonged administration of PN and has 
long been recognised as a risk factor for neonatal 
cholestasis.2 PNAC is defined as serum conjugated 
bilirubin levels of >2 mg/dL (34.2 μmol/L) associated 
with sustained exposure to PN for ≥14 days.3–5 Other 
conditions which can potentially cause cholestasis in 
infants receiving PN and which must be ruled out 
include biliary atresia and infections as well as a variety 
of other metabolic, endocrine and genetic disorders.6,7 
PNAC is predominantly a paediatric disease, with 
premature neonates being the most predisposed age 
group with high morbidity and mortality rates.4 The 
incidence, severity and duration of cholestasis varies 
substantially among reports depending on the study 
population and duration of PN exposure;3 it can vary 
from 10–60% depending on the population studied 
and the criteria used.4,8
PNAC remains a frequent and poorly understood 
complication of PN therapy in infants, despite 
improvements in the components of PN and neonatal 
intensive care measures.9 In addition, and despite an 
enhanced understanding of the molecular basis of 
neonatal cholestasis, the precise mechanism by which 
PN induces liver injury remains uncertain.10,11 Several 
risk factors for PNAC have been identified, including 
caloric overload, nutritional deficiencies, toxicity of 
specific PN constituents, oxidative stress and altered 
bile composition.12,13 In addition, intrauterine growth 
retardation, immaturity of the biliary excretory system, 
absence of enteral feeding, bacterial overgrowth, 
sepsis, hypotension or hypoxia, gastrointestinal (GI) 
surgeries, a cumulative high intake of amino acids and 
lipids and short bowel syndrome have been described 
as risk factors.9,14–21 Nutritional deficiencies, including 
essential fatty acids, carnitine, choline, taurine, 
vitamin E and selenium, are also thought to contribute 
to PNAC.22
Histologically, PNAC is associated with 
cholestasis, steatosis, steatohepatitis and, in severe 
cases, fibrosis and cirrhosis.3 The resolution of 
PNAC and normalisation of liver enzymes may occur 
gradually after the alteration or withdrawal of PN 
and the initiation of enteral feeding. However, some 
infants may develop persistent or progressive liver 
disease or hepatic failure.12 PNAC can lead to high 
morbidity and mortality rates.13,23 Numerous studies 
have documented an association between PNAC and 
risk of sepsis, liver failure and mortality.5,9 However, 
there is a lack of research investigating the incidence of 
PNAC in newborn infants in the Arab region. To the 
best of the authors’ knowledge, no studies of this kind 
have yet been undertaken in Oman. Hence, the aim 
of this study was to determine the incidence and risk 
factors of PNAC in Omani neonates for the first time.
Methods
This four-year retrospective cohort study took place 
from January to April 2014. All neonates admitted 
to the NICU at Sultan Qaboos University Hospital 
(SQUH) in Muscat, Oman, and who received PN for 
≥14 days during the period from June 2009 to May 2013 
were enrolled in the study. Exclusion criteria included 
patients who died during their time in the NICU or 
those without conjugated bilirubin measurements 
(as the cause of cholestasis could not be determined 
retrospectively) as well as neonates with other causes 
of cholestasis. A diagnosis of PNAC relied on a history 
of PN for ≥14 days, direct bilirubin of >2 mg/dL 
(34 μmol/L) and the exclusion of other causes of 
neonatal cholestasis.
Demographic and clinical data were obtained 
from hospital electronic records, including gestational 
age (GA); birth weight (BW); gender; evidence of 
Advances in Knowledge
- To the best of the authors’ knowledge, this study is the first to investigate the incidence and risk factors of parenteral nutrition-associated 
cholestasis (PNAC) in an Omani neonatal population.
- The risk factors for developing PNAC in this population were similar to those reported elsewhere. Significant risk factors for PNAC in this 
population were related to the duration of parenteral nutrition (PN) and enteral starvation, as well as the presence of late-onset sepsis 
and the number of blood transfusions and gastrointestinal surgeries a neonate had undergone. 
Application to Patient Care
- Understanding the incidence of PNAC and its risk factors in Oman will aid in the implementation of preventive strategies. These could 
include reducing the duration of PN and promoting enteral feeds soon after birth by adopting appropriate early feeding protocols in neonatal 
intensive care units. These strategies may help minimise the incidence of PNAC and prevent chronic liver disease in this age group. 
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PNAC; total duration and number of PN courses; 
ventilation; significant desaturation (oxygen saturation 
below 89%); morbidities such as respiratory distress 
syndrome (RDS), bronchopulmonary dysplasia ([BPD] 
a form of chronic lung disease that develops in preterm 
neonates treated with oxygen and positive-pressure 
ventilation), hypotension, patent ductus arteriosus 
(PDA) or necrotising enterocolitis (NEC) of any stage, 
enteral starvation, GI surgeries and a history of blood 
transfusions. The presence of late-onset sepsis was 
determined by positive blood culture results which 
are routinely done if there is any fever or suspicion 
of clinical sepsis. The use of antibiotics and potential 
hepatotoxic medications (including acetaminophen, 
diuretics, ibuprofen, morphine, sildenafil, midazolam 
and caffeine) was also documented. 
Descriptive statistics were calculated and 
compared between the PNAC and non-PNAC groups 
(the latter group included neonates in the study who 
did not develop PNAC). For categorical variables, 
frequencies and percentages were reported. Group 
comparisons were performed using the Chi-squared 
test or Fisher’s exact test where appropriate. Means 
± standard deviation or medians with interquartile 
range (IQR) were used to present the data where 
appropriate. Comparisons of continuous data were 
performed using the Student’s t-test for data with a 
normal distribution and the Mann-Whitney U test 
for continuous data without a normal distribution. 
Furthermore, a multivariate logistic regression model 
was utilised to determine risk factors for PNAC. The 
a priori two-tailed level of significance (P value) was 
set at 0.05. Data were analysed using the Statistical 
Package for the Social Sciences (SPSS), Version 20 
(IBM Corp., Chicago, Illinois, USA). 
Ethical approval for this study was obtained from 
the Medical Research & Ethics Committee at the 
College of Medicine & Health Sciences, Sultan Qaboos 
University, Muscat, Oman (MREC#622). 
Results
Between June 2009 and May 2013, a total of 1,857 
neonates were admitted to the SQUH NICU; of these, 
244 (13%) received PN during their stay. Nine neonates 
were excluded from the study either due to death 
(n = 8) or a diagnosis of cystic fibrosis (n = 1), which is 
known to cause cholestasis. Among the remaining 235 
 
Figure 1: Flowchart of Omani neonates admitted to the Sultan Qaboos University Hospital neonatal intensive care unit 
over a four-year period with regards to parenteral nutrition and parenteral nutrition-associated cholestasis.
SQUH = Sultan Qaboos University Hospital; NICU = neonatal intensive care unit; PN = parenteral nutrition; PNAC= parenteral nutrition-
associated cholestasis.
Table 1: Demographic characteristics of Omani 
neonates in a neonatal intensive care unit receiving 
parenteral nutrition for ≥14 days and evaluated for the 




Male, n (%) 56 (58)
Female, n (%) 41 (42)
GA in weeks, mean ± SD 29 ± 3
BW in g, mean ± SD 1,165 ± 495
Small for GA, n (%) 36 (37)
GA = gestational age; SD = standard deviation; BW = birth weight.
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neonates, the median duration of PN was 14 days (IQR: 
8–21 days). A total of 135 neonates (57%) received PN 
for ≥14 days and were evaluated for PNAC. A total 
of 38 neonates were subsequently excluded from the 
study due to a lack of direct bilirubin measurements, 
resulting in a total number of 97 neonates [Figure 1]. 
The demographic characteristics of these neonates are 
shown in Table 1.
Out of the 97 neonates, 38 developed PNAC, 
giving an incidence of 39% over four years. The 
details of yearly PNAC incidence rates are shown in 
Table 2. The duration of PN ranged from 14–120 days 
(mean: 30 ± 13 days). The majority of the neonates 
(34%) received PN for 2–3 weeks (14–21 days); 
these neonates demonstrated the lowest incidence of 
PNAC (12%) [Figure 2]. The incidence of PNAC was 
higher in those who had received PN for a longer 
duration [Table 2]. 
Table 3 shows the comparison between the PNAC 
and non-PNAC groups. Using a univariate analysis, the 
following significant risk factors for PNAC were found: 
PN duration; enteral starvation; presence of late-onset 
sepsis; number of blood transfusions, and GI surgeries. 
The analysis showed that the PNAC group had a 
longer median initial PN duration (30 versus 20 days; 
P <0.001), received PN more than once (24% versus 
12%; P = 0.038) and had a longer median total PN 
duration (30 versus 21 days; P <0.001) in comparison 
to neonates in the non-PNAC group. Although the 
median duration of initial enteral starvation was not 
significantly different between the PNAC and non-
PNAC groups (four and three days, respectively; 
P = 0.250), the number of neonates who underwent 
enteral starvation later on during the course of their 
NICU stay was higher (63% versus 32%; P = 0.003) 
and the median duration of total enteral starvation 
was longer in the PNAC group (11 versus five days; 
P = 0.040) compared to the non-PNAC group. 
Neonates with PNAC underwent more GI surgeries 
than those without PNAC (21% versus 5%; P = 0.015). 
Neonates in the PNAC group underwent the following 
GI surgeries: laparotomies for stage 3 NEC with 
intestinal resection (n = 3); exploratory laparotomies 
for stage 1 NEC (n = 2); laparotomy for duodenal 
atresia (n = 1), and laparotomies for malrotation and 
gastroschisis (n = 2). The non-PNAC group underwent 
the following GI surgeries: laparotomy for stage 1 NEC 
(n = 1); laparotomy and intestinal resection for stage 3 
NEC (n = 1), and duodenal atresia repair (n = 1). 
In addition, neonates with PNAC had a higher 
mean number of blood transfusions (six versus four; 
P = 0.037) and a greater frequency of late-onset sepsis 
(66% versus 41%; P = 0.016). Although neonates with 
PNAC had a higher incidence of NEC in comparison to 
those without PNAC (34% and 17% respectively), this 
difference was not significant (P = 0.051). Additionally, 
there were no significant differences between the 
PNAC and non-PNAC groups with regards to GA, 
BW, weight for GA, RDS, need for ventilation, presence 
Table 2: Yearly and total incidence of parenteral nutrition-associated cholestasis among a population of Omani 




June 2010–May 2011 June 2011–May 2012 June 2012–May 2013
Patients on PN 
for ≥14 days, n
16 19 25 37 97
PN duration in 
days, mean ± SD
36 ± 26 29 ± 14 28 ± 12 28 ± 15 30 ± 17
Patients with 
PNAC, n
8 5 10 15 38
Incidence of 
PNAC, %
50 26 40 41 39
PN = parenteral nutrition; SD = standard deviation; PNAC = parenteral nutrition-associated cholestasis. 
 
Figure 2: The incidence of PNAC in relation to the 
administration of PN for >14 days in a population 
of Omani neonates in a neonatal intensive care unit 
(N = 97).
PNAC = parenteral nutrition-associated cholestasis; PN = 
parenteral nutrition.
*Range of PN duration in this group was 57–73 days for seven 
patients and 120 days for one patient.
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of significant desaturation/hypotension, BPD or PDA 
(P >0.05) [Table 3]. 
Multivariate logistic regression revealed that only 
total PN duration was a statistically significant risk 
factor for developing PNAC (P = 0.027; odds ratio = 
1.41; 95% CI = 1.04–1.90; for each additional week of 
PN) [Table 4]. 
Discussion
To the best of the authors’ knowledge, the present 
study is the first to investigate the incidence of and risk 
factors for PNAC in an Omani neonatal population 
at an NICU in a single tertiary centre. Over the study 
period, the yearly incidence of PNAC ranged from 
26–50%, with an overall incidence of 39%. In general, 
the incidence of PNAC reportedly ranges between 10–
60% depending on the population, criteria, duration 
Table 3: Demographic and clinical characteristics 
of Omani neonates receiving PN for ≥14 days in a 
neonatal intensive care unit according to parenteral 
nutrition-associated cholestasis group (N = 97)*
Characteristic Group P 
value
PNAC 
(n = 38; 39%)
Non-PNAC 
(n = 59; 61%)
Demographic 





GA in weeks, 
mean ± SD
29 ± 3.2 28.6 ± 3.4 0.410
BW in g, mean 
± SD
1,180 ± 530 1150 ± 480 0.747
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Total AB in days, 
mean ± SD
21 ± 15 20 ± 14 0.623
Hepatotoxic medication



































PNAC = parenteral nutrition associated cholestasis; GA = gestational 
age; SD = standard deviation; BW = birth weight; SGA = small 
for gestational age; NICU = neonatal intensive care unit; RDS = 
respiratory distress syndrome; BPD = bronchopulmonary dysplasia; 
PDA= patent ductus arteriosus; NEC = necrotising enterocolitis;  PN = 
parenteral nutrition; IQR = interquartile range; GI = gastrointestinal; 
G+ = Gram-positive; G-= Gram-negative; UTI = urinary tract 
infection; AB = antibiotics.
*Statistically significant.
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of PN exposure and the components of PN.3,4,8,9 
Unfortunately, little is known regarding the incidence 
of PNAC in Arab populations. In Saudi Arabia, 
Anabrees et al. reported an incidence of 10.7% among 
neonates with a very low BW.1
PNAC has been associated with various risk 
factors, including PN duration, prematurity, low 
BW, enteral starvation, sepsis and GI surgeries. In 
the present study, the most significant risk factor for 
the development of PNAC was PN duration, which 
remained significant after regression analysis. This 
is comparable with other studies.9,24–26 In this cohort, 
the lowest PNAC incidence was observed in neonates 
who received PN for less than three weeks and the 
incidence of PNAC increased dramatically beyond 
the third week of PN. A similar study reported an 
incidence of 14% among infants receiving PN for 2–4 
weeks; this increased with total PN duration to 85% 
when PN was used for >14 weeks.9
In the current study, late-onset sepsis was an 
important risk factor for PNAC. This finding has also 
been previously reported.16,18,24,25,27 Another risk factor 
for PNAC in the studied Omani population was the 
total duration of enteral starvation; however, more 
importantly, undergoing enteral starvation later on 
during the course of the NICU stay was a significant 
risk factor. This was similarly reported in other 
studies.17,28 GI surgeries are a frequently reported 
risk factor for PNAC. Many earlier studies, as well 
as the present one, have clearly confirmed this 
relationship.9,24,25,28,29
A significant correlation between the number of 
blood transfusions and PNAC was demonstrated in 
the current study. Although there are currently no 
other published studies supporting this finding, it is 
assumed that blood transfusions in the current study 
were required for patients who were sick, septic and/
or possibly undergoing GI surgeries. Future studies 
are needed to investigate the relationship between 
blood transfusions and PNAC in order to determine 
its impact as an independent risk factor in the 
development of PNAC.
Despite its strong indication as a major risk factor 
in many other studies,9,16,26,30 the association of NEC 
with PNAC in the present study was not significant. 
Suita et al. also found no correlation between NEC and 
PNAC.28 While some studies have indicated that the 
incidence of PNAC is higher in neonates with lower 
GA and BW,9,16,24,26 other studies, including the present 
study, found no causal relationship between these 
factors.25,28 In the present study, RDS, ventilation, BPD 
and PDA were not significant risk factors for PNAC; 
this is contrary to other studies which have reported 
these factors to be associated with a higher risk of 
PNAC.16,26 Furthermore, the current study did not 
identify an association between the use of potentially 
hepatotoxic medications and increased PNAC risk.
Understanding the incidence of PNAC and its risk 
factors is important as it may aid in the implementation 
of preventive strategies so as to avoid future chronic 
liver disease and related complications in this age 
group. These strategies could include reducing the 
duration of PN and promoting enteral feeds soon 
after birth by adopting early feeding according to 
appropriate NICU protocols. These strategies may 
help minimise the incidence of PNAC and prevent 
chronic liver disease among neonates.
The present study had some limitations, including 
its retrospective nature as well as the exclusion of many 
neonates without direct bilirubin measurements due 
to the lack of laboratory monitoring or undetermined 
aetiology of the cholestasis. Furthermore, the 
constitution of PN was not examined in this study. 
Further studies are recommended to examine PN 
constituents among neonates in Oman, as well 
as identifying the effect of PN components in the 
incidence and risk factors of PNAC.
Conclusion
In the studied Omani neonatal population, the overall 
incidence of PNAC was 39% over a four-year period. 
The duration of PN, sepsis, duration of enteral starvation, 
number of GI surgeries and number of blood transfusions 
were significant risk factors for developing PNAC. 
However, only total PN duration remained a statistically 
significant risk factor after a logistic regression analysis. 
With these risk factors in mind, preventive strategies 
should be implemented in NICUs so as to avoid future 
chronic liver disease and its complications in this age 
group. To the best of the authors’ knowledge, this study 
is the first to report the incidence of PNAC and its risk 
factors among Omani neonates. 
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Table 4: Multivariate analysis for risk factors of 
parenteral nutrition-associated cholestasis among a 
population of Omani neonates in a neonatal intensive 
care unit (N = 97)
Significant risk factors P value OR 95% CI
Duration of PN 0.027 1.41 1.04–1.90
Late-onset sepsis 0.132 2.01 0.81–4.98
Duration of enteral 
starvation 
0.458 1.02 0.97–1.07
PN = parenteral nutrition; OR = odds ratio; CI = confidence interval.
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